Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

Fourteen people walked out of clinics across France, stopped their HIV medication, and stayed healthy. Not for a few weeks, but for years. Some of them for nearly a decade. And the strange part— the part that forced researchers to rethink what they knew— was that these fourteen people had none of the biological advantages that scientists had spent decades identifying as the keys to controlling HIV without drugs. That is the mystery at the heart of the ANRS VISCONTI study, led by Asier Sáez-Cirión and colleagues. The answer they found has less to do with the genetic backgrounds of these patients, and everything to do with when they started treatment. To understand why this matters, you need to know one uncomfortable truth about antiretroviral therapy. Combination antiretroviral therapy, or cART, is genuinely one of medicine's great success stories. It suppresses HIV replication, it slashes death rates, and it turns a fatal disease into a manageable one. But it does not eradicate the virus. The moment a patient stops taking it, viral replication rebounds, usually within weeks. That happens because HIV hides inside long-lived immune cells in a latent state, making it invisible to the immune system and untouchable by drugs. Those cells form what researchers call the viral reservoir, and shrinking or reshaping it is the central challenge of HIV cure research. A functional cure—not eliminating every infected cell, but achieving durable, drug-free control of the virus— is the goal. Until the VISCONTI study, the clearest examples of people who achieved something like that were a rare population known as HIV controllers: fewer than one percent of all people with HIV, who naturally suppress the virus without ever taking medication. The fourteen VISCONTI patients are something different. Sáez-Cirión and colleagues called them post-treatment controllers, or PTCs. What defined them was a specific clinical history: they all started cART within ten weeks of primary HIV infection— the earliest, most acute phase of the disease— and they took it for a prolonged period, with a median duration of thirty-six and a half months. When they stopped, their plasma viral load stayed below four hundred copies per milliliter for at least two years. Most maintained that control far longer; the median duration of remission was eighty-nine months. At the time of their primary infection, these patients were not doing well. Their median viral load at diagnosis was five log ten copies per milliliter, and their CD4-positive T cell count—the key immune cell that HIV destroys—was five hundred and two cells per microliter. Those numbers look like typical progressors, not future controllers. In contrast, eight patients from the ANRS PRIMO cohort who went on to achieve spontaneous control without drugs had a primary infection viral load of three log ten and a CD4 count of nearly eight hundred. The PTCs had a harder start; twelve of the fourteen had symptomatic primary infections. These were not people who were sailing through HIV. When the virus stayed suppressed after they stopped treatment, the obvious question was whether they simply had the same genetic advantages as spontaneous controllers— just hidden. The answer, clearly stated by Sáez-Cirión and colleagues, is no. Spontaneous HIV controllers are strongly enriched for specific variants of immune genes called HLA class I alleles—particularly HLA-B*57 and HLA-B*27. These alleles determine which fragments of viral protein get presented to CD8-positive T cells, the immune cells that hunt and kill HIV-infected cells. Having the right HLA type essentially means your immune system is unusually effective at recognizing and eliminating infected cells. Among the VISCONTI PTCs, only one carried a single HLA-B*57 allele, and two carried a single HLA-B*27. There was no overrepresentation of these protective alleles compared to the general French population. What the PTCs did carry, in high proportions, were alleles associated with worse outcomes: HLA-B*07 and HLA-B*35 accounted for twenty-nine percent of all HLA-B alleles in the group. Five PTCs carried HLA-B*35, and two of those carried the B*3503 subtype, which prior work had linked to faster progression to AIDS. The CD8-positive T cell function data reinforced this picture. In an ex vivo suppression assay— where CD8-positive T cells are tested for their ability to inhibit HIV replication in a lab dish— the PTCs were weak. Their median suppressive capacity was a 0.39 log reduction in viral protein output. For comparison, spontaneous HIV controllers achieved a median of 1.63 log reduction. Even HIV controllers who lacked the protective B*27 and B*57 alleles had a median of 1.55 log reduction. The PTCs were statistically indistinguishable from untreated viremic patients and from patients on continuous therapy. Their CD8-positive T cells were not the mechanism of their control. That is what makes the reservoir data so important. If it is not the immune response keeping these patients in remission, it has to be something about the virus itself— specifically, how little of it remains. During the period of infection control, the median level of cell-associated HIV DNA in the PTCs was 1.71 log ten copies per million peripheral blood mononuclear cells. In six patients with sequential measurements, that number dropped from a median of 2,389 copies per million cells at primary infection all the way down to 116 copies per million just before treatment interruption— a statistically significant decline, with a p-value below 0.031. And it kept going. The last available measurement, taken a median of six years after stopping treatment, showed an even lower level at 39 copies per million cells. Five of the fourteen PTCs showed a progressive decline in reservoir size over the years off treatment. Two were stable. Only one showed any sign of increasing viral activity in recent years. The reservoir was not just small; it was differently shaped. When Sáez-Cirión and colleagues sorted CD4-positive T cells into their major subpopulations and measured HIV DNA in each, they found that naïve CD4-positive T cells— the long-lived cells that would normally form the most durable reservoir— were barely infected. HIV DNA was detectable in the naïve compartment in only two of eleven PTC samples. The reservoir was instead concentrated in shorter-lived memory subsets: transitional memory cells contributed a median of fifty-four percent of the resting CD4-positive T cell reservoir, central memory contributed twenty-two percent, effector memory contributed thirteen percent, and naïve cells contributed just six percent. The virus wasn't just sitting there dormant; in vitro stimulation induced HIV production from five of six tested resting memory subsets, confirming these were functional, inducible reservoirs. The mechanistic interpretation that Sáez-Cirión and colleagues draw from this is straightforward: starting cART during the window of primary infection, before the virus has had time to seed long-lived immune compartments, limits the reservoir in both size and composition. Naïve T cells and central memory T cells— which can persist for decades— are largely spared. The remaining reservoir is weighted toward shorter-lived cells that the immune system can turn over more readily. In untreated early infection, the authors note, naïve CD4-positive T cells accumulate a median of three log copies of HIV DNA per million cells within the first month. Early treatment appears to interrupt that seeding process before it can establish a long-lived reservoir. Once the reservoir is small enough and skewed toward shorter-lived cells, the slow, quiet pressure of an intact immune system may be sufficient to keep the virus controlled— and, in some patients, continue reducing it. How often does this happen? Sáez-Cirión and colleagues estimate the probability of maintaining viral control twenty-four months after interrupting early treatment at roughly fifteen percent— far higher than the spontaneous control rate, but still a minority outcome. They are careful to note that a very small reservoir is necessary but not sufficient. Not every patient with a small reservoir after early treatment will achieve control, and other factors, still under investigation, appear to be required. What the VISCONTI study establishes is that the timing of treatment is a modifiable determinant of whether functional remission becomes possible. The fourteen PTCs were, by conventional genetic markers, unfavorably positioned— carrying risk alleles, mounting weak immune responses, and experiencing severe primary infections. What they had in common was not biology; it was the clock. They started treatment early, and that early treatment changed the landscape of their infection in ways that persisted for years after the medication stopped. This points the study toward cure research: not as a final answer, but as a proof of principle that an intervention timed correctly can reshape the infection itself— and that for some people, this reshaping may be enough. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.